A multicentre randomised controlled trial of a guided self-help cognitive behavioural therapy to MANage the impact of hot flushes and night sweats in patients with prostate CANcer undergoing androgen deprivation therapy (MANCAN2)
A multicentre randomised controlled trial of a guided self-help cognitive behavioural therapy to MANage the impact of hot flushes and night sweats in patients with prostate CANcer undergoing androgen deprivation therapy (MANCAN2)
Background: androgen deprivation therapy (ADT) is prescribed to almost half of all men diagnosed with prostate cancer. Although ADT is effective treatment, with virtually all men with advanced disease showing initial clinical response, it is associated with troublesome side effects including hot flushes and night sweats (HFNS). HFNS can be both frequent and severe and can have a significant impact on quality of life (QoL). They can occasionally be so debilitating that patients stop ADT altogether, despite the increased risk of disease relapse or death. Previous research has found that guided self-help cognitive behavioural therapy (CBT) can be effective in reducing HFNS due to ADT when delivered by a clinical psychologist. MANCAN2 aims test whether we can train the existing NHS Prostate Cancer Nurse Specialist (CNS) team to deliver guided self-help CBT and whether it is effective in reducing the impact of HFNS in men undergoing ADT.
Methods: MANCAN2 is a phase III multicentre randomised controlled trial and process evaluation. Between 144 and 196 men with prostate cancer who are currently receiving ADT and are experiencing problematic HFNS will be individually randomised in a 1:1 ratio in groups of 6-8 participants to either treatment as usual (TAU) or participation in the guided self-help CBT intervention plus TAU. A process evaluation using the normalisation process theory (NPT) framework will be conducted, to understand the CNS team's experiences of delivering the intervention and to establish the key influencers to its implementation as a routine practice service. Fidelity of implementation of the intervention will be conducted by expert assessment. The cost-effectiveness of the intervention and participant adherence to the trial intervention will also be assessed.
Discussion: MANCAN2 will advance the program of work already conducted in development of management strategies for HFNS. This research will determine whether the severity of ADT-induced HFNS in men with prostate cancer can be reduced by a guided self-help CBT intervention, delivered by the existing NHS prostate cancer CNS team, within a multicentre study. The emphasis on this existing team, if successful, should facilitate translation through to implementation in routine practice.
Trial registration: ISRCTN reference 58720120 . Registered 13 December 2022.
androgen antagonists/adverse effects, androgens, cognitive behavioral therapy, hot flashes/therapy, humans, male, neoplasm recurrence, local, prostatic neoplasms/drug therapy, quality of life, sweat
Crabb, Simon
bcd1b566-7677-4f81-8429-3ab0e85f8373
Morgan, Alannah
8153a571-1d92-4466-a992-24e7d0e1c2ec
Hunter, Myra S.
fce15222-f73f-478a-87fd-d480cac6fd2a
Stefanopoulou, Evgenia
bcc848b6-9fd5-4d30-9854-05604a129a74
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Richardson, Alison
3db30680-aa47-43a5-b54d-62d10ece17b7
Fenlon, Deborah
52f9a9f1-1643-449c-9856-258ef563342c
Fleure, Louisa
8da3eaa1-0bde-4d78-9814-3b7e6f613444
Raftery, James
27c2661d-6c4f-448a-bf36-9a89ec72bd6b
Boxall, Cherish
62deb102-02d5-4613-bd6c-7f2606367b0a
Wilding, Sam
1f316b8b-db59-4289-b6aa-183f957f3470
Nuttall, Jacqueline
154aec0a-05f2-4379-918e-9c36767fdc4c
Eminton, Zina
44904d98-97be-4080-9a84-bf5742525f8e
Tilt, Emma
e5074484-7afa-4e3a-a0bd-e17720b2dc2f
O'Neill, Alice
b144c203-ec1e-4561-b34e-ca5e35001afe
Bacon, Roger
690ac754-376e-4148-b05b-1c97ff278a52
Martin, Jonathan
521ade97-49fb-4039-b9ff-13161fbccca3
10 July 2023
Crabb, Simon
bcd1b566-7677-4f81-8429-3ab0e85f8373
Morgan, Alannah
8153a571-1d92-4466-a992-24e7d0e1c2ec
Hunter, Myra S.
fce15222-f73f-478a-87fd-d480cac6fd2a
Stefanopoulou, Evgenia
bcc848b6-9fd5-4d30-9854-05604a129a74
Griffiths, Gareth
7fd300c0-d279-4ff6-842d-aa1f2b9b864d
Richardson, Alison
3db30680-aa47-43a5-b54d-62d10ece17b7
Fenlon, Deborah
52f9a9f1-1643-449c-9856-258ef563342c
Fleure, Louisa
8da3eaa1-0bde-4d78-9814-3b7e6f613444
Raftery, James
27c2661d-6c4f-448a-bf36-9a89ec72bd6b
Boxall, Cherish
62deb102-02d5-4613-bd6c-7f2606367b0a
Wilding, Sam
1f316b8b-db59-4289-b6aa-183f957f3470
Nuttall, Jacqueline
154aec0a-05f2-4379-918e-9c36767fdc4c
Eminton, Zina
44904d98-97be-4080-9a84-bf5742525f8e
Tilt, Emma
e5074484-7afa-4e3a-a0bd-e17720b2dc2f
O'Neill, Alice
b144c203-ec1e-4561-b34e-ca5e35001afe
Bacon, Roger
690ac754-376e-4148-b05b-1c97ff278a52
Martin, Jonathan
521ade97-49fb-4039-b9ff-13161fbccca3
Crabb, Simon, Morgan, Alannah, Hunter, Myra S., Stefanopoulou, Evgenia, Griffiths, Gareth, Richardson, Alison, Fenlon, Deborah, Fleure, Louisa, Raftery, James, Boxall, Cherish, Wilding, Sam, Nuttall, Jacqueline, Eminton, Zina, Tilt, Emma, O'Neill, Alice, Bacon, Roger and Martin, Jonathan
(2023)
A multicentre randomised controlled trial of a guided self-help cognitive behavioural therapy to MANage the impact of hot flushes and night sweats in patients with prostate CANcer undergoing androgen deprivation therapy (MANCAN2).
Trials, 24 (1), [450].
(doi:10.1186/s13063-023-07325-w).
Abstract
Background: androgen deprivation therapy (ADT) is prescribed to almost half of all men diagnosed with prostate cancer. Although ADT is effective treatment, with virtually all men with advanced disease showing initial clinical response, it is associated with troublesome side effects including hot flushes and night sweats (HFNS). HFNS can be both frequent and severe and can have a significant impact on quality of life (QoL). They can occasionally be so debilitating that patients stop ADT altogether, despite the increased risk of disease relapse or death. Previous research has found that guided self-help cognitive behavioural therapy (CBT) can be effective in reducing HFNS due to ADT when delivered by a clinical psychologist. MANCAN2 aims test whether we can train the existing NHS Prostate Cancer Nurse Specialist (CNS) team to deliver guided self-help CBT and whether it is effective in reducing the impact of HFNS in men undergoing ADT.
Methods: MANCAN2 is a phase III multicentre randomised controlled trial and process evaluation. Between 144 and 196 men with prostate cancer who are currently receiving ADT and are experiencing problematic HFNS will be individually randomised in a 1:1 ratio in groups of 6-8 participants to either treatment as usual (TAU) or participation in the guided self-help CBT intervention plus TAU. A process evaluation using the normalisation process theory (NPT) framework will be conducted, to understand the CNS team's experiences of delivering the intervention and to establish the key influencers to its implementation as a routine practice service. Fidelity of implementation of the intervention will be conducted by expert assessment. The cost-effectiveness of the intervention and participant adherence to the trial intervention will also be assessed.
Discussion: MANCAN2 will advance the program of work already conducted in development of management strategies for HFNS. This research will determine whether the severity of ADT-induced HFNS in men with prostate cancer can be reduced by a guided self-help CBT intervention, delivered by the existing NHS prostate cancer CNS team, within a multicentre study. The emphasis on this existing team, if successful, should facilitate translation through to implementation in routine practice.
Trial registration: ISRCTN reference 58720120 . Registered 13 December 2022.
Text
s13063-023-07325-w
- Version of Record
More information
Accepted/In Press date: 12 April 2023
Published date: 10 July 2023
Additional Information:
Funding Information:
Recruitment is supported by the research nurses and staff at secondary care NHS sites across England and Wales. The pre- and post-intervention workshops are delivered by the existing prostate cancer nurse specialist team at secondary care NHS sites across England and Wales. At the end of the study, once the analysis has taken place and results become available, a summary of research findings will be sent to all participants who request to receive these (there is an item on the ICF where participants can consent to receive the trial results). Results will be disseminated through the scientific community by peer-reviewed publications and conference presentation. We will keep the patient community up to date and involved throughout the entire process through the Prostate Cancer Support Organisation (PCaSO) and other patient support groups and social media. The TMG will form the basis of the Writing Committee and advise on the nature of publications. All publications shall include a list of investigators, and if there are named authors, these should include the chief investigator, co-investigators, trial management team, and statistician(s) involved in the trial. Named authors will be agreed by the CI and director of SCTU. If there are no named authors, then a ‘writing committee’ will be identified.
Keywords:
androgen antagonists/adverse effects, androgens, cognitive behavioral therapy, hot flashes/therapy, humans, male, neoplasm recurrence, local, prostatic neoplasms/drug therapy, quality of life, sweat
Identifiers
Local EPrints ID: 479801
URI: http://eprints.soton.ac.uk/id/eprint/479801
ISSN: 1745-6215
PURE UUID: 89185098-287c-4d4f-b734-58c0b27ffa9c
Catalogue record
Date deposited: 26 Jul 2023 17:08
Last modified: 18 Mar 2024 03:14
Export record
Altmetrics
Contributors
Author:
Alannah Morgan
Author:
Myra S. Hunter
Author:
Evgenia Stefanopoulou
Author:
Deborah Fenlon
Author:
Louisa Fleure
Author:
Cherish Boxall
Author:
Sam Wilding
Author:
Jacqueline Nuttall
Author:
Zina Eminton
Author:
Emma Tilt
Author:
Alice O'Neill
Author:
Roger Bacon
Author:
Jonathan Martin
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics